Optimizing Target Specificity, Patient Selection & Clinical Endpoints of TGF-β Directed Mono & Combination Therapies to Boost Clinical Efficacy in Immuno-Oncology, Fibrosis & Beyond
EVENT CANCELLED
Hanson Wade Group have taken the decision to cancel this meeting.
Please accept our apologies for any inconvenience or disappointment caused.
Register your interest if you would like updates on the meeting or topic.
Welcome to the TGF-B Targeted Drug Development Summit
With 128 TGF-B targeted therapies in the clinic and 68 in the preclinical stage, the TGF-B field is currently being rejuvenated by novel approaches in immuno-oncology, and cutting-edge research in fibrosis, autoimmune diseases, and beyond.
The TGF-B Targeted Drug Development Summit returns to San Francisco to deep dive into the hottest topics in the field, such as combination strategies being employed by Genentech and discovering new and predictive biomarkers from Corbus Pharmaceuticals. This meeting will support you in securing clinical success with safe and efficacious TGF-B targeted therapies.
With a program consisting of TGF-B industry leaders such as Cue Biopharma, Synthis, and Pfizer, this year promises to spotlight innovative ways biotech and large pharma companies are overcoming toxicity, translation, and proving clinical efficacy. Join us in October to celebrate the accomplishments of the TGF-B field and anticipate the future towards clinically effective and approved TGF-B targeted therapies.
Our Previously Attended Companies
